FATE
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Fate Therapeutics, Inc. (FATE) [ST]
www.fatetherapeutics.com ↗▲ 12.37%
prev close
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
-1
0 buys · 1 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2023-01-31 | FATEFate Therapeutics, Inc. | Sell | $1,001 - $15,000 | 1334d ago | — |
2023-01-31
Daniel Goldman
FATE
Amount
$1,001 - $15,000
Filed
1334d ago
Recent News
Powered by Polygon.io
Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsight
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight
Trade Timeline
Congressional activity, newest first
Daniel Goldman
2023-01-31 · Sale
$1,001 - $15,000